- Home
- LUNR vs AUPH Comparison
LUNR vs AUPH Comparison
Compare LUNR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNR
- AUPH
- Stock Information
- Founded
- LUNR 2013
- AUPH 1993
- Country
- LUNR United States
- AUPH Canada
- Employees
- LUNR N/A
- AUPH 300
- Industry
- LUNR Industrial Machinery/Components
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- LUNR Industrials
- AUPH Health Care
- Exchange
- LUNR Nasdaq
- AUPH Nasdaq
- Market Cap
- LUNR 1.3B
- AUPH 1.2B
- IPO Year
- LUNR N/A
- AUPH 1999
- Fundamental
- Price
- LUNR $12.82
- AUPH $8.93
- Analyst Decision
- LUNR Buy
- AUPH Strong Buy
- Analyst Count
- LUNR 7
- AUPH 2
- Target Price
- LUNR $14.43
- AUPH $11.50
- AVG Volume (30 Days)
- LUNR 8.6M
- AUPH 2.1M
- Earning Date
- LUNR 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- LUNR N/A
- AUPH N/A
- EPS Growth
- LUNR N/A
- AUPH N/A
- EPS
- LUNR N/A
- AUPH 0.27
- Revenue
- LUNR $217,305,000.00
- AUPH $247,295,000.00
- Revenue This Year
- LUNR $20.31
- AUPH $12.15
- Revenue Next Year
- LUNR $43.28
- AUPH $18.34
- P/E Ratio
- LUNR N/A
- AUPH $33.57
- Revenue Growth
- LUNR 61.52
- AUPH 29.20
- 52 Week Low
- LUNR $3.15
- AUPH $5.20
- 52 Week High
- LUNR $24.95
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- LUNR 61.71
- AUPH 57.25
- Support Level
- LUNR $10.72
- AUPH $8.73
- Resistance Level
- LUNR $13.60
- AUPH $9.37
- Average True Range (ATR)
- LUNR 0.92
- AUPH 0.41
- MACD
- LUNR 0.19
- AUPH 0.04
- Stochastic Oscillator
- LUNR 75.38
- AUPH 77.28
About LUNR Intuitive Machines Inc.
Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure. The Company operates in one operating segment and one reportable segment underpinned by three core pillars (delivery services, data transmission services, and infrastructure as a service) that have similar capabilities, customers, and economic characteristics. Revenue is from contracts with customers of orbital and lunar access services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.